Predictors of Boolean2.0 remission in rheumatoid arthritis identified using smart disease management system data

Abstract Rheumatoid arthritis (RA) is a chronic inflammatory disease requiring early diagnosis and treatment to achieve sustained clinical remission. Achieving a state of remission is associated with favorable outcomes. However, predictive factors for Boolean2.0 remission in RA patients are limited....

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Yuqi Zhang, Keqian Du, Bin Wu, Yongfu Wang, Hua Wei, Xiaoxue Feng, Jia Xu, Peijun Xu, Jianlin Huang
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-04-01
Subjects:	Rheumatoid arthritis Boolean2.0 remission Predictors Treatment Disease-modifying antirheumatic drugs
Online Access:	https://doi.org/10.1038/s41598-025-97084-2

Similar Items

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE
by: E. L. Nasonov, et al.
Published: (2018-07-01)

LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124)
by: E. L. Nasonov, et al.
Published: (2018-07-01)

Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials
by: Grace C. Wright, et al.
Published: (2024-07-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)

ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2018-05-01)

Serum IL-40 increases in patients with rheumatoid arthritis and correlates with some clinical characteristics and comorbidities
by: Wei Wang, et al.
Published: (2024-11-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
by: Marta Madej, et al.
Published: (2019-08-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain
by: R. Ariza, et al.
Published: (2014-07-01)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
by: Noriko Kimura, et al.
Published: (2019-03-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

Disease Activity in Disease Modifying Anti-Rheumatic Drug (DMARD) Naïve Rheumatoid Arthritis Patients in A Subset of Karachi Population
by: Dr. Mehreen Inam Illahi, et al.
Published: (2024-05-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Peculiarities of pharmacotherapy of patients with rheumatoid arthritis associated with interstitial lung disease
by: A. V. Gordeev, et al.
Published: (2024-02-01)

A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis
by: Kirsten Janke, et al.
Published: (2022-12-01)

Cytokine Signatures as Biomarkers of Clinical Remission in Rheumatoid Arthritis
by: Su W, et al.
Published: (2025-06-01)

Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis
by: Samina A. Turk, et al.
Published: (2018-06-01)

The application value of MRI in the diagnosis of subclinical inflammation in patients with rheumatoid arthritis in remission
by: Huimei Zhang, et al.
Published: (2018-07-01)

Rheumatoid arthritis – medication dosage in chronic kidney disease
by: Kinga Maria Tyczyńska, et al.
Published: (2024-01-01)

Optical imaging (HandScan) can identify ultrasound remission in rheumatoid arthritis
by: Charline Rinkin, et al.
Published: (2024-05-01)

Intensive therapy and remissions in rheumatoid arthritis: a systematic review
by: Catherine D. Hughes, et al.
Published: (2018-10-01)

Evaluation of difficult-to-treat rheumatoid arthritis using EULAR definition: Prevalence and clinical determinants from a single-center cross-sectional study
by: Sevilay Batibay, et al.
Published: (2025-04-01)

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
by: Marina G. Birck, et al.
Published: (2025-07-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

The long-term remission of rheumatoid arthritis with a single cycle of rituximab
by: Glišić Branislava, et al.
Published: (2012-01-01)

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study
by: Kosuke Ebina, et al.
Published: (2019-04-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem
by: N. V. Chichasova, et al.
Published: (2024-12-01)

Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis
by: Patricia Ruiz-Limón, et al.
Published: (2025-01-01)

Sustained remission of rheumatoid arthritis following COVID-19 vaccination
by: Angelo Nigro
Published: (2025-06-01)

COVID-19 and post-covid syndrome in patients with rheumatoid arthritis
by: E. S. Aronova, et al.
Published: (2023-08-01)